DAA Treatment for HCV Reduced Healthcare Service Utilization in a Population of Individuals With HIV/HCV Coinfection in Canada

March 8-11, 2020; Boston, Massachusetts
Reduced inpatient and outpatient visits observed following SVR with oral HCV DAA therapy in real-world HIV/HCV-coinfected population.
Format: Microsoft PowerPoint (.ppt)
File Size: 154 KB
Released: March 17, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 21, 2022

Clinical Care Options (CCO) presents expert faculty discussing the barriers and solutions to expanding PrEP uptake, from a nursing perspective

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
person default Christopher Fox, MSN, RN, ANP-BC, AAHIVS
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2022 Expired: June 13, 2023

Expert analysis of barriers and solutions to PrEP uptake in key populations

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: May 31, 2022

Breve vlog del Dr. Luis E. Soto-Ramírez sobre la optimización del TAR en una paciente con VIH en edad fértil en México de Clinical Care Options (CCO)

Luis E. Soto-Ramirez, MD Released: May 31, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings